Phase I Clinical Trial of Autologous Ascites-derived Exosomes Combined With GM-CSF for Colorectal Cancer
Authors:
Top Cited Papers
Open Access
- 1 April 2008
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 16 (4) , 782-790
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Human Tumor-Derived Exosomes Selectively Impair Lymphocyte Responses to Interleukin-2Cancer Research, 2007
- Pattern and prognostic factors in patients with malignant ascites: a retrospective studyAnnals of Oncology, 2007
- Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cellsJournal of Cancer Research and Clinical Oncology, 2007
- Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patientsAnnals of Oncology, 2006
- Expression of CCL20 and Granulocyte-Macrophage Colony-Stimulating Factor, but Not Flt3-L, from Modified Vaccinia Virus Ankara Enhances Antiviral Cellular and Humoral Immune ResponsesJournal of Virology, 2006
- Direct stimulation of T cells by membrane vesicles from antigen-presenting cellsProceedings of the National Academy of Sciences, 2006
- Dendritic cell derived-exosomes: biology and clinical implementationsJournal of Leukocyte Biology, 2006
- Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical OutcomeJournal of Clinical Oncology, 2005
- The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancerVaccine, 2005
- Exosome-based immunotherapyCancer Immunology, Immunotherapy, 2004